NCT01616758View on ClinicalTrials.gov

Phase II Study of GTx024 in Women With Metastatic Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

March 31, 2016

Conditions
Metastatic Breast Cancer
Interventions
DRUG

GTx-024 9mg

Trial Locations (4)

33145

AMPM Research Clinic, Miami

61615

Illinois Cancer Care, PC, Peoria

02110

Dana Farber Cancer Institute, Boston

01841

Commonwealth Hematology-Oncology, Lawrence

Sponsors

Lead Sponsor

GTx
All Listed Sponsors
lead

GTx

INDUSTRY

NCT01616758 - Phase II Study of GTx024 in Women With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter